TMCnet News
CRWENews Highlights: IBM, ACTC(M2 PressWIRE Via Acquire Media NewsEdge) Las Vegas CRWENews.com is pleased to announce a stock highlight on IBM (NYSE: IBM), Advanced Cell Technology, Inc. (OTCBB:ACTC) IBM (NYSE: IBM) announced today November 19, 2009 offers 10 new software products to help lower application management costs by optimizing the System z mainframe for more workloads, such as data analytics, collaborative application development, application maintenance and other key business processes. Given System z's ability to reduce costs through server consolidation, IBM and the industry have aggressively extended the breadth of new workloads for the mainframe via 3,800 z/OS-based and 3,000 Linux-based applications. The unique ability of the mainframe to host many application services on one system has helped System z achieve one of the industry's lowest application costs per user. Minimal application costs are important for companies which rely on multiple applications to run their business. About IBM International Business Machines Corporation (IBM) develops and manufactures information technology products and services worldwide. Advanced Cell Technology Files IND With FDA For First Human Clinical Trial Using Embryonic Stem Cells to Treat Eye Disease Advanced Cell Technology, Inc. (OTCBB:ACTC) announced today November 19, 2009 filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD). As many as 10 million people in the United States have photoreceptor degenerative disease. The treatment for eye disease uses stem cells to re-create a type of cell in the retina that supports the photoreceptors needed for vision. These cells, called retinal pigment epithelium (RPE), are often the first to die off in SMD and AMD, which in turn leads to loss of vision. About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. Sign up to receive FREE Stock-PR alerts from CRWENewswire.com at http://www.crwenewswire.com/c/stock-pr About CRWENews.com CRWENews.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENews.com is a division of Crown Equity Holdings, Inc. CRWENews.com is not a registered investment advisor or broker-dealer. CRWENews.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above. We encourage investors to join and receive CRWENews.com FREE e-mail news and stock watch alerts at http://www.crwenewswire.com/c/stock-pr and view our full disclaimer. Forward-Looking Statement: This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements. ((Comments on this story may be sent to [email protected])) (c) 2009 M2 COMMUNICATIONS |